Status:
COMPLETED
Vancomycin-Associated Nephrotoxicity
Lead Sponsor:
University at Buffalo
Collaborating Sponsors:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions:
Nephrotoxicity
Eligibility:
All Genders
18+ years
Brief Summary
The primary goal of this study is to determine if there is an association between greater exposure to vancomycin and the development of nephrotoxicity. The secondary goal is to estimate the costs to t...
Eligibility Criteria
Inclusion
- 18 years or older at time of hospital admission
- Had an absolute neutrophil count of ≥ 1000 cells/mm\^3
- Received \> 48 hours of intravenous vancomycin therapy
- Had one or more vancomycin trough levels reported within the 96 hours after therapy initiation
- Had a baseline serum creatinine level of \< 2.0 mg/dL and baseline creatinine clearance level of ≥ 30 mL/min
Exclusion
- Previous diagnosis of cystic fibrosis
Key Trial Info
Start Date :
November 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
398 Patients enrolled
Trial Details
Trial ID
NCT01216540
Start Date
November 1 2010
End Date
April 1 2011
Last Update
October 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rochester Medical Center
Rochester, New York, United States, 14642